Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Conclusions: PARP inhibitors can be used as a single agent for maintenance therapy for platinum-sensitive recurrent disease in patients with partial or complete response following 2 or more rounds of platinum-based therapy.
PMID: 32172572 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Kerliu L, Myruski S, Bhatti A, Soni P, Petrosius P, Pervanas HC, Horton ER Tags: Ann Pharmacother Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Epithelial Cancer | Fallopian Tube Cancer | Gastroschisis Repair | Genetics | Ovarian Cancer | Ovaries | Peritoneal Cancer | Study | Thrombocytopenia | Websites